Innovative Antimicrobial Peptide Chewing Gum Shows Promise in Reducing Plaque and Gingival Inflammation

Posted: December 1, 2024
A recent study conducted Phase 1 and 2a clinical trials to assess the safety and efficacy of a novel antimicrobial peptide, KSL-W, incorporated into chewing gum. This peptide targets cariogenic bacteria without disrupting the oral microbiome like conventional agents. The trials, approved by the FDA, demonstrated the safety of KSL-W at various doses, with promising results in reducing plaque and gingival inflammation. The optimal dose of 30 mg showed significant effectiveness without adverse reactions. These findings suggest the potential of KSL-W in improving oral health by combating plaque and gingival issues. Further research is needed to determine optimal usage and safety in diverse populations.

This article summary was generated by AI. To view the full article, click the link here: https://pubmed.ncbi.nlm.nih.gov/39466933/
Views: 24
Sponsors
Townie Perks
Townie® Poll
Who or what do you turn to for most financial advice regarding your practice?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@farranmedia.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450